Oddo Bhf set a €116.00 ($134.88) price objective on MorphoSys (ETR:MOR) in a research report released on Thursday morning. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on MorphoSys and gave the company a buy rating in a report on Thursday, July 19th. Royal Bank of Canada set a €62.00 ($72.09) price objective on MorphoSys and gave the company a sell rating in a report on Thursday, July 19th. Independent Research set a €120.00 ($139.53) price objective on MorphoSys and gave the company a neutral rating in a report on Tuesday, August 7th. Berenberg Bank set a €108.00 ($125.58) price objective on MorphoSys and gave the company a neutral rating in a report on Friday, September 7th. Finally, Goldman Sachs Group set a €86.00 ($100.00) price objective on MorphoSys and gave the company a neutral rating in a report on Wednesday, September 26th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of €96.40 ($112.09).

Shares of MorphoSys stock opened at €106.20 ($123.49) on Thursday. MorphoSys has a fifty-two week low of €49.63 ($57.71) and a fifty-two week high of €88.10 ($102.44).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Featured Article: Why do companies issue stock splits?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.